

JosÃ© M Porcel, Facp, Fccp, Fers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3704971/publications.pdf>

Version: 2024-02-01

129
papers

4,433
citations

94269

37
h-index

118652

62
g-index

138
all docs

138
docs citations

138
times ranked

3048
citing authors

#	ARTICLE	IF	CITATIONS
1	Applications of CRISPR technology to lung cancer research. <i>European Respiratory Journal</i> , 2022, 59, 2102610.	3.1	6
2	Cell-Free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions. <i>Annals of the American Thoracic Society</i> , 2022, 19, 854-856.	1.5	4
3	Some pleural effusions labeled as idiopathic could be produced by the inhalation of silica. <i>Pleura and Peritoneum</i> , 2022, .	0.5	1
4	Management of recurrent transudative pleural effusions: can we REDUCE unnecessary interventions?. <i>European Respiratory Journal</i> , 2022, 59, 2101942.	3.1	2
5	A Simple Scoring System to Differentiate Bacterial from Viral Infections in Acute Exacerbations of COPD Requiring Hospitalization. <i>International Journal of COPD</i> , 2022, Volume 17, 773-779.	0.9	5
6	Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response. <i>Cancers</i> , 2022, 14, 2529.	1.7	1
7	Recommendations of the Spanish Society of Thoracic Surgery for the management of malignant pleural effusion. <i>Cirugía Española (English Edition)</i> , 2022, .	0.1	0
8	Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer. <i>Pleura and Peritoneum</i> , 2021, 6, 75-81.	0.5	6
9	Pleural Infection Caused by <i>Nocardia farcinica</i> : Two Cases and Review of the Literature. <i>Cureus</i> , 2021, 13, e14697.	0.2	1
10	Dr. Richard W. Light (1942-2021). <i>Archivos De Bronconeumología</i> , 2021, 57, 512-512.	0.4	2
11	Ambulatory management of secondary spontaneous pneumothorax: a mirage, or a solution on the horizon?. <i>European Respiratory Journal</i> , 2021, 57, 2100003.	3.1	0
12	Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions. <i>Cancers</i> , 2021, 13, 2798.	1.7	20
13	The Eponymous Dr. Richard W. Light: Father of Pleural Medicine. <i>Archivos De Bronconeumología</i> , 2021, .	0.4	0
14	Dr. Richard W. Light (1942–2021). <i>Archivos De Bronconeumología</i> , 2021, 57, 512.	0.4	0
15	Recent Insights into the Management of Pleural Infection. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3415-3429.	0.8	21
16	Thoracoscopy for Spontaneous Pneumothorax. <i>Journal of Clinical Medicine</i> , 2021, 10, 3835.	1.0	9
17	Pleural Effusions Identified by Point-of-Care Ultrasound Predict Poor Outcomes in Decompensated Cirrhosis. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 3283-3290.	0.7	3
18	Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 162, 106-118.	0.9	13

#	ARTICLE	IF	CITATIONS
19	Pleural Fluid Analysis. Clinics in Chest Medicine, 2021, 42, 599-609.	0.8	13
20	Time to embrace POCUS as part of the bedside diagnosis of respiratory diseases. Respirology, 2020, 25, 466-467.	1.3	5
21	Predictors of Indwelling Pleural Catheter Removal and Infection. Journal of Bronchology and Interventional Pulmonology, 2020, 27, 86-94.	0.8	22
22	Experimental supporting data on the influence of platelet-derived factors of malignant pleural effusions on T cell effector functions and their relevance in predicting prognosis of lung adenocarcinoma patients with pleural metastasis. Data in Brief, 2020, 32, 106266.	0.5	0
23	Neumomediastino espontáneo en la dermatomiositis. Archivos De Bronconeumologia, 2020, 56, 668.	0.4	2
24	PILOTing towards a RAPID predictor of mortality for infectious pleural effusions. European Respiratory Journal, 2020, 56, 2002425.	3.1	3
25	Platelet factor 4 regulates T cell effector functions in malignant pleural effusions. Cancer Letters, 2020, 491, 78-86.	3.2	8
26	Pleural diseases and COVID-19: ubi fumus, ibi ignis. European Respiratory Journal, 2020, 56, 2003308.	3.1	10
27	Rheumatoid pseudochylothorax. Archivos De Bronconeumologia, 2020, 56, 666-667.	0.4	0
28	Seudoquilotax reumatoide. Archivos De Bronconeumologia, 2020, 56, 666-667.	0.4	0
29	PLEASE, take a deep breath. European Respiratory Journal, 2020, 55, 2000501.	3.1	3
30	Natriuretic peptides in pleural effusions: Beyond a diagnosis of heart failure. Respirology, 2020, 25, 1021-1022.	1.3	1
31	Two vs. three weeks of treatment with amoxicillin-clavulanate for stabilized community-acquired complicated parapneumonic effusions. A preliminary non-inferiority, double-blind, randomized, controlled trial. Pleura and Peritoneum, 2020, 5, 20190027.	0.5	12
32	An Inexpensive Way to Drain Malignant Effusions With Indwelling Pleural Catheters and Its Impact on Performance Status and Pleurodesis. Experience from a Tertiary Hospital in México. Open Respiratory Archives, 2020, 2, 194-196.	0.0	1
33	Derrame pleural tuberculoso: características clínicas de 320 pacientes. Archivos De Bronconeumologia, 2019, 55, 17-22.	0.4	13
34	Eficacia diagnóstica de la adenosina desaminasa en líquido pleural para diagnosticar tuberculosis. Metaanálisis de estudios españoles. Archivos De Bronconeumologia, 2019, 55, 23-30.	0.4	16
35	Pleural Effusions: Overview and Diagnostic Approach. , 2019, , .		0
36	EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer. Scientific Reports, 2019, 9, 15057.	1.6	31

#	ARTICLE	IF	CITATIONS
37	EV-Associated miRNAs from Peritoneal Lavage are a Source of Biomarkers in Endometrial Cancer. <i>Cancers</i> , 2019, 11, 839.	1.7	27
38	Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions. <i>Respirology</i> , 2019, 24, 799-804.	1.3	5
39	Relationship of pleural fluid pH and glucose: a multi-centre study of 2,971 cases. <i>Journal of Thoracic Disease</i> , 2019, 11, 123-130.	0.6	15
40	Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients. <i>Scientific Reports</i> , 2019, 9, 2996.	1.6	15
41	Dual intracavitary therapy for pleural infections: leaving reluctance behind. <i>European Respiratory Journal</i> , 2019, 54, 1901001.	3.1	5
42	Ultrasound-based elastography: ¿how hard to implement in the pleural effusion work-up?. <i>European Respiratory Journal</i> , 2019, 54, 1901587.	3.1	9
43	Diagnosis and characterization of malignant effusions through pleural fluid cytological examination. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 362-368.	1.2	22
44	Pleural Effusions in Diffuse Large B-Cell Lymphoma: Clinical and Prognostic Significance. <i>Lung</i> , 2019, 197, 47-51.	1.4	19
45	Cambios en los parámetros bioquímicos del líquido pleural entre 2 toracocentesis consecutivas para diferenciar derrames malignos de benignos. <i>Archivos De Bronconeumología</i> , 2018, 54, 320-326.	0.4	1
46	Pleural effusions in acute decompensated heart failure: Prevalence and prognostic implications. <i>European Journal of Internal Medicine</i> , 2018, 52, 49-53.	1.0	23
47	Secondary spontaneous pneumothorax in idiopathic pulmonary fibrosis: Grim news. <i>Respirology</i> , 2018, 23, 448-449.	1.3	5
48	Chest imaging for the diagnosis of complicated parapneumonic effusions. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 398-402.	1.2	3
49	Minimally invasive treatment of complicated parapneumonic effusions and empyemas in adults. <i>Clinical Respiratory Journal</i> , 2018, 12, 1361-1366.	0.6	13
50	Development and validation of a scoring system for the identification of pleural exudates of cardiac origin. <i>European Journal of Internal Medicine</i> , 2018, 50, 60-64.	1.0	14
51	CT versus thoracic ultrasound for discriminating uncomplicated and complicated parapneumonic pleural effusions – Reply. <i>Respirology</i> , 2018, 23, 232-233.	1.3	2
52	Improving the management of spontaneous pneumothorax. <i>European Respiratory Journal</i> , 2018, 52, 1801918.	3.1	1
53	Biomarkers in the diagnosis of pleural diseases: a 2018 update. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880866.	1.0	75
54	Phenotyping primary spontaneous pneumothorax. <i>European Respiratory Journal</i> , 2018, 52, 1801455.	3.1	5

#	ARTICLE	IF	CITATIONS
55	Management of pleural infections. Expert Review of Respiratory Medicine, 2018, 12, 521-535.	1.0	31
56	ERS/EACTS statement on the management of malignant pleural effusions. European Respiratory Journal, 2018, 52, 1800349.	3.1	179
57	Chest Tube Drainage of the Pleural Space: A Concise Review for Pulmonologists. Tuberculosis and Respiratory Diseases, 2018, 81, 106.	0.7	68
58	Detection of Pleural Fluid Biochemistry Changes in Two Consecutive Thoracenteses for Differentiating Malignant From Benign Effusions. Archivos De Bronconeumologia, 2018, 54, 320-326.	0.4	0
59	Computed tomography scoring system for discriminating between parapneumonic effusions eventually drained and those cured only with antibiotics. Respirology, 2017, 22, 1199-1204.	1.3	36
60	Utilidad de la medición de CEA y CA 15-3 en los exudados pleurales no purulentos para diagnosticar malignidad: experiencia de un único centro. Archivos De Bronconeumologia, 2017, 53, 427-431.	0.4	13
61	Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion. Lung, 2017, 195, 775-779.	1.4	20
62	Diagnóstico y manejo de los trasudados pleurales. Archivos De Bronconeumologia, 2017, 53, 629-636.	0.4	20
63	Utility of CEA and CA 15-3 Measurements in Non-Purulent Pleural Exudates in the Diagnosis of Malignancy: A Single-Center Experience. Archivos De Bronconeumologia, 2017, 53, 427-431.	0.4	4
64	Manual Intrapleural Saline Flushing Plus Urokinase: A Potentially Useful Therapy for Complicated Parapneumonic Effusions and Empyemas. Lung, 2017, 195, 135-138.	1.4	14
65	Advances in the diagnosis of tuberculous pleuritis. Annals of Translational Medicine, 2016, 4, 282-282.	0.7	69
66	Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers. Medicine (United States), 2016, 95, e3044.	0.4	11
67	Development and Validation of the COMPLES Score for Differentiating Between Tuberculous Effusions with Low Pleural pH or Glucose and Complicated Parapneumonic Effusions. Lung, 2016, 194, 847-854.	1.4	2
68	Malignant pleural effusion: from bench to bedside. European Respiratory Review, 2016, 25, 189-198.	3.0	179
69	Clinical features and survival of lung cancer patients with pleural effusions. Respirology, 2015, 20, 654-659.	1.3	164
70	CEA and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions. Respirology, 2015, 20, 831-833.	1.3	9
71	Distinguishing complicated from uncomplicated parapneumonic effusions. Current Opinion in Pulmonary Medicine, 2015, 21, 346-351.	1.2	20
72	Accuracy of Fluorodeoxyglucose-PET Imaging for Differentiating Benign From Malignant Pleural Effusions. Chest, 2015, 147, 502-512.	0.4	103

#	ARTICLE	IF	CITATIONS
73	Predictors of Clinical Use of Pleurodesis and/or Indwelling Pleural Catheter Therapy for Malignant Pleural Effusion. <i>Chest</i> , 2015, 147, 1629-1634.	0.4	35
74	Derivation and Validation of a CT Scan Scoring System for Discriminating Malignant From Benign Pleural Effusions. <i>Chest</i> , 2015, 147, 513-519.	0.4	68
75	Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study. <i>Lung</i> , 2015, 193, 993-1000.	1.4	48
76	The diagnosis of pleural effusions. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 801-815.	1.0	64
77	Management of refractory hepatic hydrothorax. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 352-357.	1.2	44
78	Etiology of Pleural Effusions: Analysis of More Than 3,000 Consecutive Thoracenteses. <i>Archivos De Bronconeumologia</i> , 2014, 50, 161-165.	0.4	80
79	Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas. <i>Archivos De Bronconeumologia</i> , 2014, 50, 161-165.	0.4	216
80	Imaging of pleural effusions: a pictorial review. <i>Current Respiratory Care Reports</i> , 2014, 3, 42-44.	0.6	3
81	Serum C-Reactive Protein as an Adjunct for Identifying Complicated Parapneumonic Effusions. <i>Lung</i> , 2014, 192, 577-581.	1.4	14
82	Year in review 2012: Lung cancer, respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging. <i>Respirology</i> , 2013, 18, 573-583.	1.3	2
83	Pleural Fluid Biomarkers. <i>Clinics in Chest Medicine</i> , 2013, 34, 27-37.	0.8	60
84	Pleural effusions. <i>Disease-a-Month</i> , 2013, 59, 29-57.	0.4	92
85	Identifying transudates misclassified by Light's criteria. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 362-367.	1.2	44
86	Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure. <i>Respirology</i> , 2013, 18, 540-545.	1.3	8
87	Diagnosis exjuvantibus of a persistent pleural effusion. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2013, 3, 22466.	0.4	1
88	Clinical implications of pleural effusions in ovarian cancer. <i>Respirology</i> , 2012, 17, 1060-1067.	1.3	34
89	Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. <i>European Journal of Internal Medicine</i> , 2012, 23, 447-450.	1.0	55
90	Contarini's syndrome: Bilateral pleural effusion, each side from different causes. <i>Journal of Hospital Medicine</i> , 2012, 7, 164-165.	0.7	13

#	ARTICLE	IF	CITATIONS
91	Diagnosis of pleural infection: state-of-the-art. <i>Current Respiratory Care Reports</i> , 2012, 1, 101-110.	0.6	8
92	Year in review 2011: Respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging. <i>Respirology</i> , 2012, 17, 573-582.	1.3	3
93	Solving the Light's criteria misclassification rate of cardiac and hepatic transudates. <i>Respirology</i> , 2012, 17, 721-726.	1.3	75
94	The Use of Pleural Fluid sCD44v6/std Ratio for Distinguishing Mesothelioma from Other Pleural Malignancies. <i>Journal of Thoracic Oncology</i> , 2011, 6, 190-194.	0.5	5
95	Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure. <i>Current Opinion in Pulmonary Medicine</i> , 2011, 17, 215-219.	1.2	34
96	Pearls and myths in pleural fluid analysis. <i>Respirology</i> , 2011, 16, 44-52.	1.3	91
97	Triggering receptor (TREM-1) expressed on myeloid cells predicts bacteremia better than clinical variables in community-acquired pneumonia. <i>Respirology</i> , 2011, 16, 321-325.	1.3	17
98	Tumor Type Influences the Effectiveness of Pleurodesis in Malignant Effusions. <i>Lung</i> , 2011, 189, 151-155.	1.4	60
99	Pleural fluid tests to identify complicated parapneumonic effusions. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 357-361.	1.2	48
100	Year in review 2009: Respiratory infections, tuberculosis, pleural diseases and lung cancer. <i>Respirology</i> , 2010, 15, 562-572.	1.3	1
101	Pleural Effusions from Congestive Heart Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 689-697.	0.8	58
102	Diagnostic performance of adenosine deaminase activity in pleural fluid: A single-center experience with over 2100 consecutive patients. <i>European Journal of Internal Medicine</i> , 2010, 21, 419-423.	1.0	148
103	Biomarkers of infection for the differential diagnosis of pleural effusions. <i>European Respiratory Journal</i> , 2009, 34, 1383-1389.	3.1	103
104	Tuberculous Pleural Effusion. <i>Lung</i> , 2009, 187, 263-270.	1.4	244
105	Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. <i>Respirology</i> , 2009, 14, 105-111.	1.3	62
106	Establishing a diagnosis of pleural effusion due to heart failure. <i>Respirology</i> , 2009, 14, 471-473.	1.3	12
107	High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions. <i>European Journal of Internal Medicine</i> , 2009, 20, 383-386.	1.0	27
108	Biomarkers of Heart Failure in Pleural Fluid. <i>Chest</i> , 2009, 136, 671-677.	0.4	63

#	ARTICLE	IF	CITATIONS
109	Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions. <i>Respirology</i> , 2008, 13, 58-62.	1.3	33
110	C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease. <i>Respirology</i> , 2008, 13, 1028-1033.	1.3	26
111	A decision tree for differentiating tuberculous from malignant pleural effusions. <i>Respiratory Medicine</i> , 2008, 102, 1159-1164.	1.3	42
112	Prognostic significance of pleural fluid data in patients with malignant effusion. <i>European Journal of Internal Medicine</i> , 2008, 19, 334-339.	1.0	94
113	Diagnostic and Prognostic Implications of Pleural Adhesions in Malignant Effusions. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1251-1256.	0.5	39
114	Pleural effusions due to pulmonary embolism. <i>Current Opinion in Pulmonary Medicine</i> , 2008, 14, 337-342.	1.2	26
115	Classification tree analysis for the discrimination of pleural exudates and transudates. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 82-7.	1.4	6
116	Contribution of a Pleural Antigen Assay (Binax NOW) to the Diagnosis of Pneumococcal Pneumonia. <i>Chest</i> , 2007, 131, 1442-1447.	0.4	57
117	Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis. <i>Lupus</i> , 2007, 16, 25-27.	0.8	40
118	Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. <i>Respirology</i> , 2007, 12, 117-121.	1.3	16
119	Analysis of pleural effusions in acute pulmonary embolism: Radiological and pleural fluid data from 230 patients. <i>Respirology</i> , 2007, 12, 234-239.	1.3	51
120	Comparing serum and pleural fluid pro-brain natriuretic peptide (NT-proBNP) levels with pleural-to-serum albumin gradient for the identification of cardiac effusions misclassified by Light's criteria. <i>Respirology</i> , 2007, 12, 654-659.	1.3	45
121	Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions. <i>Respiratory Medicine</i> , 2006, 100, 933-937.	1.3	50
122	Bayesian analysis using continuous likelihood ratios for identifying pleural exudates. <i>Respiratory Medicine</i> , 2006, 100, 1960-1965.	1.3	18
123	Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. <i>Supportive Care in Cancer</i> , 2006, 14, 475-478.	1.0	34
124	Distribution of Pleural Effusion in Congestive Heart Failure. <i>Southern Medical Journal</i> , 2006, 99, 98-99.	0.3	10
125	Diagnostic approach to pleural effusion in adults. <i>American Family Physician</i> , 2006, 73, 1211-20.	0.1	139
126	The use of probrain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions resulting from heart failure. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 329-333.	1.2	20

#	ARTICLE	IF	CITATIONS
127	Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions. <i>Clinical Biochemistry</i> , 2005, 38, 1031-1033.	0.8	9
128	Use of a Panel of Tumor Markers (Carcinoembryonic Antigen, Cancer Antigen 125, Carbohydrate) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 and Malignant Effusions. <i>Chest</i> , 2004, 126, 1757-1763.	0.4	187
129	Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer. , 1999, 72, 167-174.		27